Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response

ClinicalTrials.gov ID: NCT00285376

Public ClinicalTrials.gov record NCT00285376. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 27, 2026, 10:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

Study identification

NCT ID
NCT00285376
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Genaissance Pharmaceuticals
Industry
Enrollment
410 participants

Conditions and interventions

Interventions

  • vilazodone Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2006
Primary completion
Apr 30, 2007
Completion
Apr 30, 2007
Last update posted
Feb 20, 2008

2006 – 2007

United States locations

U.S. sites
15
U.S. states
9
U.S. cities
15
Facility City State ZIP Site status
Pharmacology Research Institute Los Alamitos California 90720
Pharmacology Research Institute Newport Beach California 92660
Pharmacology Research Institute Northridge California 91324
Pharmacology Research Institute Riverside California 92506
Atlanta Institute of Medicine & Research Atlanta Georgia 30328
Atlanta Institute of Medicine & Research Marietta Georgia 30060
Summit Research Network (Michigan), Inc. Farmington Hills Michigan 48336
Summit Research Network (Michigan), Inc. Flint Michigan 48507
Social Psychiatry Research Institute Brooklyn New York 11235
Summit Research Network (Oregon) Inc. Portland Oregon 97210
University of Pennsylvania Department of Psychiatry Mood and Anxiety Disorders Section Philadelphia Pennsylvania 19104-3309
Southeast Health Consultants, LLC Charleston South Carolina 29407
University of Utah health Services Center Dept. of Psychiatry Mood and Anxiety Disorders Salt Lake City Utah 84132
Northwest Clinical Research Center Bellevue Washington 98004
Summit Research Network (Seattle) LLC Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00285376, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 20, 2008 · Synced Jun 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00285376 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →